Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Trial Profile

Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Combretastatin A1 phosphate (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mateon Therapeutics
  • Most Recent Events

    • 12 Dec 2017 Results (n=18) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 30 Oct 2017 Mateon is in the process of expanding the size of future, higher-dose cohorts to 10 patients to increase the utility of the data generated, as reported a media release.
    • 30 Oct 2017 Updated data from the fifth dose cohort of this trial published in the Mateon Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top